Sandoz And Polpharma Strike Global Deal For Natalizumab
Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.
Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.